<DOC>
	<DOCNO>NCT03087864</DOCNO>
	<brief_summary>Objectives The primary objective study assess feasibility preoperative treatment atezolizumab combine preoperative chemoradiation ( carboplatin , paclitaxel radiation ) term completion treatment atezolizumab .</brief_summary>
	<brief_title>PDL-1 Targeting Resectable Oesophageal Cancer</brief_title>
	<detailed_description>Objectives The primary objective study study assess feasibility preoperative treatment atezolizumab combine preoperative chemoradiation ( carboplatin , paclitaxel radiation ) term completion treatment atezolizumab . Secondary objective : - To assess toxicity atezolizumab alone combination chemoradiation . - To assess completion chemotherapy radiation treatment - To assess withdrawal rate surgery - To assess post-operative complication . - To assess pathological response . - To assess R0 resection rate . - To assess relation gut microbiota composition response . - To assess relation gut microbiota composition toxicity . Explorative objective : To perform exploratory biomarker analyse tumor tissue blood-derived sample correlate safety clinical outcome . Biomarker analyse include ( limited ) : - Expression PD-1 , PD-L1 FOXP3 , presence tumor infiltrate CD8+/CD4+ cytotoxic/helper T lymphocytes , IFNγ expression , presence tumor macrophage , STAT3 STAT6 expression , MHC classI , MHC class II , EBV MSI status tumor tissue . - RNA sequence whole exome sequence develop predictive profile response treatment . - Analysis ctDNA extract plasma patient four time point ( baseline , directly chemoradiation , surgery 3 month surgery ) analyze use Ion Torrent Next Generation sequence technology non-invasive marker response treatment . - Analysis peripheral blood mononuclear cell ( PBMCs ) extract whole blood patient three time point ( ( baseline , directly chemoradiation , surgery ) ) - Duodenal biopsy morning faeces sample analysis predictor response do HIT Chip flora mapping , establish sensitive RT-qPCR method develop exact sensitive enumeration bacterial population .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically proven adenocarcinoma esophagus gastro esophageal junction . Surgical resectable ( &lt; T4b , N0 N+ , M0 ) , determine Endoscopic Ultra Sound ( EUS ) CT scan neck , thorax abdomen . Tumors pass endoscope endoscopic ultrasound eligible criterion fulfil . T1N+ tumor eligible . Tumor length longitudinal ≤ 10 cm ; large 10 cm , inclusion discuss principal investigator . If tumor extends gastroesophageal ( GE ) junction proximal stomach , bulk tumor must involve esophagus GE junction . Age ≥ 18 . ECOG performance status 0 1 ( cf . Appendix A ) . Adequate hematological , renal hepatic function define : neutrophile ≥ 1.5 x 109/L platelet ≥ 100 x 109/L hemoglobin ≥ 5.6 mmol total bilirubin ≤ 1.5 x upper normal limit creatinine clearance ( Cockroft ) &gt; 60 ml/min Written , voluntary inform consent Patients must accessible follow management treatment center Past current history malignancy entry diagnosis interfere prognosis esophageal cancer . Invasion tracheobronchial tree presence tracheoesophageal fistula . T1N0 tumor situ carcinoma . Pregnancy ( positive serum pregnancy test ) , plan become pregnant , lactation . Patient ( male female ) willing use highly effective method contraception ( per institutional standard ) treatment 6 month ( male female ) end treatment . Previous chemotherapy , radiotherapy , and/or treatment checkpoint inhibitor . Clinically significant cardiovascular disease ( include myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) preclude major surgery . Pulmonary fibrosis and/or severely impaired lung function preclude major surgery . Preexisting motor sensory neurotoxicity great WHO grade 1 . Serious underlie medical condition would impair ability patient receive plan treatment , include prior allergic reaction drug contain Cremophor , teniposide cyclosporine . Dementia alter mental status would prohibit understanding give informed consent Inadequate caloric and/or fluid intake despite consultation dietician and/or tube feeding . Has active autoimmune disease require systemic treatment past 2 year ( i.e . use disease modify agent , corticosteroid immunosuppressive drug ) . Replacement therapy ( e.g. , thyroxine patient history autoimmunerelated hypothyroidism , insulin patient type 1 diabetes mellitus , physiologic corticosteroid replacement therapy adrenal pituitary insufficiency , etc . ) consider form systemic treatment . Patients vitiligo dermatological manifestation eligible enter study . Has diagnosis immunodeficiency receive systemic steroid therapy ( &gt; 10 mg/day prednisone equivalent ) form immunosuppressive therapy within 7 day prior first dose trial treatment . Has evidence interstitial lung disease active , noninfectious pneumonitis . Has active infection require systemic therapy resolve 3 day ( simple infection cystitis ) 7 day ( severe infection pyelonephritis ) prior first dose trial treatment . Patients prior allogeneic stem cell solid organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>esophageal cancer</keyword>
	<keyword>PD-L1 inhibition</keyword>
	<keyword>chemoradiation</keyword>
</DOC>